Canine Arthritis Treatment Market Forecasts to 2030 – Global Analysis By Type (Osteoarthritis, Rheumatoid Arthritis and Juvenile Idiopathic Arthritis), By Treatment Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs

Canine Arthritis Treatment Market Forecasts to 2030 – Global Analysis By Type (Osteoarthritis, Rheumatoid Arthritis and Juvenile Idiopathic Arthritis), By Treatment Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Disease-Modifying Antirheumatic Drugs (DMARDs) and Other Treatment Types), Route of Administration, Distribution Channel and By Geography

According to Stratistics MRC, the Global Canine Arthritis Treatment Market is accounted for $2.3 billion in 2023 and is expected to reach $3.2 billion by 2030 growing at a CAGR of 5.2% during the forecast period. Canine arthritis treatment involves various approaches to managing pain and inflammation in dogs affected by arthritis. These may include medication such as nonsteroidal anti-inflammatory drugs (NSAIDs), supplements like glucosamine and chondroitin, physical therapy, weight management, and lifestyle modifications. In severe cases, surgery may be necessary. The goal is to improve mobility, reduce discomfort, and enhance the quality of life for affected dogs.

According to the American Pet Products Association, an estimated 94.2 million cats and 89.7 million dogs are owned by households in the U.S. during 2017.

Market Dynamics:

Driver:

Rising pet ownership and expenditure on pet healthcare

The increasing trend of pet ownership worldwide has significantly contributed to the growth of the canine arthritis treatment market. As more people embrace pets as integral members of their families, there's a corresponding rise in expenditure on pet healthcare, including treatment for conditions like canine arthritis. Pet owners are increasingly willing to invest in advanced medical care and therapies to ensure the health and well-being of their furry companions, driving demand for innovative treatments and boosting the overall market for canine arthritis treatment.

Restraint:

High cost associated with advanced treatment options

The high cost associated with advanced treatment options, such as stem cell therapy and orthopedic surgeries, presents a significant financial barrier for pet owners seeking comprehensive care for canine arthritis. These advanced treatments often entail substantial expenses, potentially deterring individuals from pursuing them. Consequently, pet owners may resort to less expensive alternatives or even forego treatment altogether due to financial constraints. This affordability challenge underscores the need for accessible and cost-effective solutions to ensure optimal care for pets suffering from arthritis.

Opportunity:

Growing demand for minimally invasive treatment options

Pet owners are increasingly seeking less invasive procedures that offer quicker recovery times and reduce the risk of complications for their furry companions. Minimally invasive techniques, such as arthroscopy and laser therapy, are gaining popularity due to their efficacy and minimal disruption to the pet's lifestyle. This trend presents an opportunity for veterinary clinics and manufacturers to develop and offer innovative, minimally invasive treatments to meet the evolving needs of pet owners and their arthritic pets.

Threat:

Potential side effects and risks associated with certain treatment modalities

Treatments like non-steroidal anti-inflammatory drugs (NSAIDs) or corticosteroids can alleviate symptoms, but they may also lead to adverse reactions such as gastrointestinal issues or renal complications. Such risks may deter pet owners from pursuing these treatments, impacting their willingness to opt for conventional therapies. Consequently, ensuring the safety and efficacy of canine arthritis treatments is essential to mitigating potential threats to market acceptance and pet well-being.

Covid-19 Impact:

The COVID-19 pandemic has influenced the canine arthritis treatment market by altering veterinary care access and pet ownership behaviors. Restrictions on non-essential services and economic uncertainties have led to decreased veterinary visits, affecting diagnosis and treatment. Additionally, financial constraints have influenced pet owners' willingness to invest in advanced treatments, impacting market growth and emphasizing the need for affordable care options.

The nonsteroidal anti-inflammatory drugs (NSAIDs) segment is expected to be the largest during the forecast period

In the canine arthritis treatment market, the nonsteroidal anti-inflammatory drugs (NSAIDs) segment is projected to dominate during the forecast period. This dominance can be attributed to several factors, including their widespread use as a conventional treatment option for managing arthritis-related pain and inflammation in dogs. Additionally, NSAIDs are often preferred by veterinarians due to their efficacy and relatively low cost compared to other advanced treatment modalities, contributing to their anticipated prominence in the market.

The injectables segment is expected to have the highest CAGR during the forecast period

In the canine arthritis treatment market, the injectables segment is projected to experience the highest growth during the forecast period. This growth is attributed to several factors, including the convenience of administration, efficacy in delivering targeted treatment, and the development of innovative injectable therapies. Additionally, advancements in formulation technologies and a shift towards minimally invasive treatment options are driving the demand for injectables, contributing to their anticipated rapid growth trajectory.

Region with largest share:

Over the forecast period, North America is poised to dominate the canine arthritis treatment market. This is due to a large population of pet owners with high disposable income, a well-established veterinary healthcare infrastructure, and advanced research and development activities. Additionally, increasing awareness about pet health and a growing trend towards the humanization of pets further contribute to the region's prominence. Consequently, North America is expected to maintain its leading position in the canine arthritis treatment market in the foreseeable future.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is poised for rapid growth in the canine arthritis treatment market. This is due to increasing pet ownership rates, rising disposable incomes, and growing awareness of pet healthcare, which are driving demand for arthritis treatments. Additionally, improving veterinary infrastructure and the adoption of advanced treatment modalities are enhancing accessibility to care. As a result, the Asia-Pacific region presents significant opportunities for market expansion, attracting investments, and fostering innovation in canine arthritis treatment solutions.

Key players in the market

Some of the key players in Canine Arthritis Treatment Market include Boehringer Ingelheim Animal Health, Ceva Santé Animale, Dechra Pharmaceuticals PLC, Elanco Animal Health, Hill's Pet Nutrition, InVivo Therapeutics Corporation, Mars Petcare, Merck Animal Health, Norbrook Laboratories, Nutramax Laboratories, Inc., OrthoPets LLC, Rejuvenate Bio, Royal Canin, Veterinary Orthopedic Implants Inc., Vetoquinol S.A., Virbac and Zoetis Inc.

Key Developments:

In February 2024, Rejuvenate Bio partnered with a leading animal health company to develop and commercialize groundbreaking gene therapy for canine osteoarthritis, aiming to address the condition's widespread prevalence and devastating consequences, potentially revolutionizing dog health. This agreement with the global company follows the agreement reached in 2022 with Phibro Animal Health and further validates the gene therapy technology developed by Rejuvenate Bio and their strategy to develop their breakthrough technology in both animal health and human health.

In May 2023, The Food and Drug Administration (FDA) approved Librela, for the control of canine OA pain in the U.S. The first and only injectable monoclonal antibody (mAb) treatment for canine OA is expected to be available in late 2023. A once-monthly injection administered by a veterinary professional, Librela (bedinvetmab injection) works differently than other pain medications, according to a May 5 release from Zoetis.

Types Covered:
• Osteoarthritis
• Rheumatoid Arthritis
• Juvenile Idiopathic Arthritis

Treatment Types Covered:
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Disease-Modifying Antirheumatic Drugs (DMARDs)
• Corticosteroids
• Nutraceuticals
• Physical Therapy and Rehabilitation
• Stem Cell Therapy
• Surgery
• Other Treatment Types

Route of Administrations Covered:
• Oral
• Injectables
• Topical

Distribution Channels Covered:
• Veterinary Clinics and Hospitals
• Retail Pharmacies
• Online Pharmacies

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances